Introducing Arietta.ai’s LucidPV— Advanced AI in Pharmacovigilance

Prescription pharmaceuticals improve lives every day, but licensed products can still cause side effects. The practice of pharmacovigilance is critical to patient safety, ensuring manufacturers monitor, report to regulators, and assess when medications cause adverse events. Within the domain of Pharmacovigilance, fast and accurate analysis and action on adverse drug events benefits all stakeholders within healthcare including patients and caregivers, providers, insurers, regulators, and life sciences manufacturers. As more information on the medications in circulation and the resulting patient experience is collected, Arietta.ai’s pioneer product, LucidPV, is poised to shorten the time to process adverse events and speed analysis and insight by drug manufacturers and regulators. 

The market for life-changing medications is growing each year, with Reuters reporting that 45-50 new FDA-approved medications enter the market annually. While these medications hold promise for many patients, responding swiftly and efficiently to adverse event reports and modifying use guidelines helps protect patients and maximize the therapeutic benefit of medications. Pharmacovigilance is ideally suited to leverage AI based intake and triage to accelerate insights and increase patient safety. Arietta.ai aims to change this by harnessing the power of advanced artificial intelligence to support automated processing of adverse events to meet compliance requirements and deliver accelerated insights leading to increased patient safety.  

Existing approaches to pharmacovigilance are heavily dependent upon human input and manual processes. Medical providers, patients, and caregivers need a way to easily report adverse events associated with pharmaceuticals to support public health. Pharmaceutical companies need to process and report these adverse events in a timely and accurate manner. As budgets decrease, manufacturers are struggling to stay effective with case-processing productivity. Artificial intelligence can assist these teams to do more with less, all while reducing costs within the first year. In as little as three months, the LucidPV large language model (LLM) based AI platform can free up employee hours, improve pharmacovigilance-oriented processes, and lay the foundation for a high return on investment. 

Few industries are more heavily dependent upon compliance and turnaround times than life sciences, so finding efficiencies in critical processes is essential to keeping pace, especially when patient safety is on the line. LucidPV is designed to support adverse event intake and triage, allowing it to accelerate the early stages of processing, including the initial processing and book-in for cases as they are reported to clinics. These processes are carried out while maintaining privacy and protections to support better internal compliance efforts. “Arietta.ai’s LucidPV was built for the life science industry with regulatory considerations in mind,” says Tim Howard, CEO of Arietta.ai, highlighting the ability to leverage emerging technologies to enhance compliance and accelerate insights. “Our AI framework incorporates the strongest data privacy and support for emerging regulatory guidelines while improving the pharmacovigilance processes for teams.” 

Historically, humans have worked to fit their processes around technology. With the introduction of artificial intelligence, this relationship with technology is changing quickly. Teams do not adapt themselves to fit around artificial intelligence solutions. Instead, AI systems seamlessly integrate themselves into teams, working to understand their processes and identify efficiencies. In this way, artificial intelligence systems are not just tools—they are partners. Teams have everything to gain by adding AI support to their workflows. LucidPV was made to assist medical teams on every level, offering support for scalability to meet the size of any provider, all while offering transparency for the teams that use it, learning alongside them to improve their internal processes.  

Artificial intelligence can assess, analyze, and process information at unimaginable speeds. These systems can review high volumes of data and effortlessly lock onto critical elements within that information, offering support for swift and relevant trends. By speeding up these processes, AI can help life science firms recognize growing trends with certain medications and may even be able to recognize signals faster than traditional methods, allowing swift responses. The information derived from these systems does not just help companies to optimize operations—it empowers them to provide better health outcomes 

Improving the speed and consistency of pharmacovigilance will have a positive impact on individual patient safety and public health for years to come. It also stands to improve the way life sciences manufacturers respond to real world evidence, and to improve the patient and provider experience with medicines.  As more teams adopt AI into their PV workflows, transparency and consistency will help medical professionals in every focus better understand the potential impacts of new and existing medications on the market. With Arietta.ai’s LucidPV’s LLM-based intake and triage solution, life science companies are able to improve the safety of their medications.